ALX Oncology presents updated data from ASPEN-06 Phase 2 trial

ALX Oncology (ALXO) announced positive updated data from the ASPEN-06 Phase 2 clinical trial demonstrating that the company’s investigational CD47-blocker evorpacept generates a durable clinical response with a well-tolerated safety profile among patients with previously treated HER2-positive advanced gastric cancer or gastroesophageal junction cancer. Primary endpoints: ITT patient population ORR: Evorpacept plus TRP demonstrated an ORR of 41.3% compared to 30% for RP historical control and 26.6% for TRP control. Fresh HER2-positive biopsy patient population ORR: ETRP demonstrated an ORR of 59.1% compared to 30% for RP historical control and 23.1% for TRP control